Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has told investors it expects to complete patient enrollment of its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19) in the first quarter of 2022.
In a statement clarifying the status of the trial, the life sciences company noted that as of December 29 last year, there had been around 700 subjects who had "participated in the enrollment period" of the study.
"In addition, the company has begun the process to expand the study’s patient population in Turkey in collaboration with Delta Health, which will add research sites from the largest hospital group in Turkey, MLP Care and Istinye University," the company said in a brief statement.
READ: Revive Therapeutics expands patient enrollment for Phase 3 clinical trial of Bucillamine for COVID-19 in Eastern Europe, Asia
Revive said it expects patient enrollment in Turkey to occur by mid-February this year.
The study is aimed at evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases and rare disorders, and aims to take advantage of several regulatory incentives awarded by the US Food & Drug Administration (FDA) such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations.
Contact the writer at giles@proactiveinvestors.com